( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2019/0382802 A1
Total Page:16
File Type:pdf, Size:1020Kb
INDUS 20190382802A1 IN (19 ) United States (12 ) Patent Application Publication ( 10) Pub. No .: US 2019/0382802 A1 Keasling et al. (43 ) Pub . Date : Dec. 19 , 2019 (54 ) GENETICALLY MODIFIED HOST CELLS Publication Classification AND USE OF SAME FOR PRODUCING ( 51 ) Int. Ci. ISOPRENOID COMPOUNDS C12P 5/00 (2006.01 ) C12N 9/10 (2006.01 ) (71 ) Applicant: The Regents of the University of C12N 15/81 (2006.01 ) California , Oakland , CA (US ) C12P 23/00 (2006.01 ) C12N 9/04 (2006.01 ) ( 72 ) Inventors : Jay D. Keasling, Berkeley , CA (US ) ; C12N 9/88 ( 2006.01 ) James Kirby , Berkeley , CA (US ) ; Eric (52 ) U.S. CI. M. Paradise , Vienna , VA (US ) CPC C12P 5/007 ( 2013.01) ; C12N 9/1085 ( 2013.01 ) ; C12N 15/81 ( 2013.01 ) ; C12P 23/00 ( 2013.01 ); C12Y 402/03024 ( 2013.01) ; C12N ( 21) Appl. No .: 16 /554,125 9/88 ( 2013.01 ) ; C12Y 101/01034 (2013.01 ) ; C12Y 205/01092 (2013.01 ) ; C12N 9/0006 ( 2013.01) ( 22 ) Filed : Aug. 28 , 2019 (57 ) ABSTRACT The present invention provides genetically modified eukary otic host cells that produce isoprenoid precursors or iso Related U.S. Application Data prenoid compounds. A subject genetically modified host cell ( 63 ) Continuation of application No. 15/ 722,844 , filed on comprises increased activity levels of one or more of Oct. 2 , 2017 , now Pat . No. 10,435,717 , which is a mevalonate pathway enzymes , increased levels of prenyl continuation of application No. 14 /451,056 , filed on transferase activity , and decreased levels of squalene syn Aug. 4 , 2014 , now Pat. No. 9,809,829 , which is a thase activity . Methods are provided for the production of an continuation of application No. 11/ 571,315 , filed on isoprenoid compound or an isoprenoid precursor in a subject Nov. 13 , 2007, now Pat . No. 8,828,684 , filed as genetically modified eukaryotic host cell . The methods application No. PCT/ US2005 /026190 on Jul. 21, generally involve culturing a subject genetically modified 2005 . host cell under conditions that promote production of high ( 60 ) Provisional application No. 60 /592,009 , filed on Jul. levels of an isoprenoid or isoprenoid precursor compound . 27 ,9 2004 . Specification includes a Sequence Listing . Patent Application Publication Dec. 19 , 2019 Sheet 1 of 8 US 2019/0382802 A1 H3Cvia SCOA Acetyl - CoA 1 ERG10 H?? SCOA Acetoacetyl- COA ERG13 H3C OH O HO2C SCOA HMG - COA HMG1 HMG2 H3C OH HO2C OH Mevalonate ERG 12 H3C OH HO2C OPO3 Mevalonate - P ERG8 H3C OH HO2C OPO3PO3 Mevalonate -PP ERG19 IDI1 th OPO3PO3 OPO3PO3 Isopentenyl diphosphate ( IPP ) Dimethylallyl diphosphate (DMAPP ) FIG . 1 Patent Application Publication Dec. 19 , 2019 Sheet 2 of 8 US 2019/0382802 A1 diene11-Amorpha4, Dimethylallyldiphosphate(DMAPP) OPO3PO3 ERG20 ADSADS OPO3PO3 OPO3P03 IDI1 Geranyldiphosphate(GPP) ERG20 Farnesyldiphosphate(FPP) OPO3PO3 diphosphateIPP)Isopentenyl( FIG.2 IPP ERG9 Squalene 4 ERG1,7,11,24,25,6,2,3,4,5Ergosterolcopy HO Patent Application Publication Dec. 19, 2019 Sheet 3 of 8 US 2019/0382802 A1 HH 100 80 4060 Time(h) ADStHMGR&+ +ECM22&ADS FIG.3B ADS UPC2&ADS* 20 0 5.00 4.0 3.0 2.0 1.0 0.0 ) OD600/ mL / equivalent caryophyllene ug( Production Amorphadiene 100 80 60 Time(h) ADStHMGR&- +UPC2&ADS +ECM22&ADS FIG.3A 40 ADS 20 15.00 12.00 9.00 6.00 3.004 0.00+ ) OD600/ mL /equivalent caryophyllene ug( Production Amorphadiene Patent Application Publication Dec. 19, 2019 Sheet 4 of 8 US 2019/0382802 A1 10.00 9.00 - 64 hours 8.00 - N 87 hours 7.00 6.00 OD600equivalent/)mLcaryophyllene(ug 5.00 - ProductionAmorphadine 4.00 - 3.00 1. = 2.00 - 1.00 0.00 0 0.1 0.3 0.5 1 Methionine Concentration (MM ) FIG . 4 Patent Application Publication Dec. 19, 2019 Sheet 5 of 8 US 2019/0382802 A1 90.0 ads 80.0 hmgr upc2 70.0 + erg9 60.0 * erg20 (ugcaryophylleneequivalent/mLOD600) 50.0 ProductionAmorphadiene 40.0 30.0 20.0 10.0 0.0 0 24 48 72 96 120 144 Time (h ) FIG . 5 Patent Application Publication Dec. 19, 2019 Sheet 6 of 8 US 2019/0382802 A1 FIG . 6 Truncated HMGR coding sequence ATGGTTTTAACCAATAAAACAGTCATTTCTGGATCGAAAGTCAAAAGTTTATCATCTGCGCAATCGAGCTC ATCAGGACCTTCATCATCTAGTGAGGAAGATGATTCCCGCGATATTGAAAGCTTGGATAAGAAAATACGTC CTTTAGAAGAATTAGAAGCATTATTAAGTAGTGGAAATACAAAACAATTGAAGAACAAAGAGGTCGCTGCC TTGGTTATTCACGGTAAGTTACCTTTGTACGCTTTGGAGAAAAAATTAGGTGATACTACGAGAGCGGTTGC GGTACGTAGGAAGGCTCTTTCAATTTTGGCAGAAGCTCCTGTATTAGCATCTGATCGTTTACCATATAAAA ATTATGACTACGACCGCGTATTTGGCGCTTGTTGTGAAAATGTTATAGGTTACATGCCTTTGCCCGTTGGT GTTATAGGCCCCTTGGTTATCGATGGTACATCTTATCATATACCAATGGCAACTACAGAGGGTTGTTTGGT AGCTTCTGCCATGCGTGGCTGTAAGGCAATCAATGCTGGCGGTGGTGCAACAACTGTTTTAACTAAGGATG GTATGACAAGAGGCCCAGTAGTCCGTTTCCCAACTTTGAAAAGATCTGGTGCCTGTAAGATATGGTTAGAC TCAGAAGAGGGACAAAACGCAATTAAAAAAGCTTTTAACTCTACATCAAGATTTGCACGTCTGCAACATAT TCAAACTTGTCTAGCAGGAGATTTACTCTTCATGAGATTTAGAACAACTACTGGTGACGCAATGGGTATGA ATATGATTTCTAAAGGTGTCGAATACTCATTAAAGCAAATGGTAGAAGAGTATGGCTGGGAAGATATGGAG GTTGTCTCCGTTTCTGGTAACTACTGTACCGACAAAAAACCAGCTGCCATCAACTGGATCGAAGGTCGTGG TAAGAGTGTCGTCGCAGAAGCTACTATTCCTGGTGATGTTGTCAGAAAAGTGTTAAAAAGTGATGTTTCCG CATTGGTTGAGTTGAACATTGCTAAGAATTTGGTTGGATCTGCAATGGCTGGGTCTGTTGGTGGATTTAAC GCACATGCAGCTAATTTAGTGACAGCTGTTTTCTTGGCATTAGGACAAGATCCTGCACAAAATGTTGAAAG TTCCAACTGTATAACATTGATGAAAGAAGTGGACGGTGATTTGAGAATTTCCGTATCCATGCCATCCATCG AAGTAGGTACCATCGGTGGTGGTACTGTTCTAGAACCACAAGGTGCCATGTTGGACTTATTAGGTGTAAGA GGCCCGCATGCTACCGCTCCTGGTACCAACGCACGTCAATTAGCAAGAATAGTTGCCTGTGCCGTCTTGGC AGGTGAATTATCCTTATGTGCTGCCCTAGCAGCCGGCCATTTGGTTCAAAGTCATATGACCCACAACAGGA AACCTGCTGAACCAACAAAACCTAACAATTTGGACGCCACTGATATAAATCGTTTGAAAGATGGGTCCGTC ACCTGCATTAAATCCTAA ( SEQ ID NO : 1 ) Patent Application Publication Dec. 19 , 2019 Sheet 7 of 8 US 2019/0382802 A1 FIG . 7A Met Val Leu Thr Asn Lys Thr Val Ile Ser Gly Ser Lys Val Lys Ser 1 5 10 15 Leu Ser Ser Ala Gln Ser Ser Ser Ser Gly Pro Ser Ser Ser Ser Glu 20 25 30 Glu Asp Asp Ser Arg Asp Ile Glu Ser Leu Asp Lys Lys Ile Arg Pro 35 40 45 Leu Glu Glu Leu Glu Ala Leu Leu Ser Ser Gly Asn Thr Lys Gin Leu 50 55 60 Lys Asn Lys Glu Val Ala Ala Leu Val Ile His Gly Lys Leu Pro Leu 65 70 75 80 Tyr Ala Leu Glu Lys Lys Leu Gly Asp Thr Thr Arg Ala Val Ala Val 85 90 95 Arg Arg Lys Ala Leu Ser Ile Leu Ala Glu Ala Pro Val Leu Ala Ser 100 105 110 Asp Arg Leu Pro Tyr Lys Asn Tyr Asp Tyr Asp Arg Val Phe Gly Ala 115 120 125 Cys Cys Glu Asn Val Ile Gly Tyr Met Pro Leu Pro Val Gly Val Ile 130 135 140 Gly Pro Leu Val Ile Asp Gly Thr Ser Tyr His Ile Pro Met Ala Thr 145 150 155 160 Thr Glu Gly Cys Leu Val Ala Ser Ala Met Arg Gly Cys Lys Ala Ile 165 170 175 Asn Ala Gly Gly Gly Ala Thr Thr Val Leu Thr Lys Asp Gly Met Thr 180 185 190 Arg Gly Pro Val Val Arg Phe Pro Thr Leu Lys Arg Ser Gly Ala Cys 195 200 205 Lys Ile Trp Leu Asp Ser Glu Glu Gly Gin Asn Ala Ile Lys Lys Ala 210 215 220 Phe Asn Ser Thr Ser Arg Phe Ala Arg Leu Gin His Ile Gin Thr Cys 225 230 235 240 Leu Ala Gly Asp Leu Leu Phe Met Arg Phe Arg Thr Thr Thr Gly Asp 245 250 255 Ala Met Gly Met Asn Met Ile Ser Lys Gly Val Glu Tyr Ser Leu Lys 260 265 270 Gln Met Val Glu Glu Tyr Gly Trp Glu Asp Met Glu Val Val Ser Val 275 280 285 Ser Gly Asn Tyr Cys Thr Asp Lys Lys Pro Ala Ala Ile Asn Trp Ile 290 295 300 Glu Gly Arg Gly Lys Ser Val Val Ala Glu Ala Thr Ile Pro Gly Asp 305 310 315 320 Val Val Arg Lys Val Leu Lys Ser Asp Val Ser Ala Leu Val Glu Leu 325 330 335 Asn Ile Ala Lys Asn Leu Val Gly Ser Ala Met Ala Gly Ser Val Gly 340 345 350 Gly Phe Asn Ala His Ala Ala Asn Leu Val Thr Ala Val Phe Leu Ala 355 360 365 Leu Gly Gln Asp Pro Ala Gin Asn Val Glu Ser Ser Asn Cys Ile Thr 370 375 380 Leu Met Lys Glu Val Asp Gly Asp Leu Arg Ile Ser Val Ser Met Pro 385 390 395 400 Patent Application Publication Dec. 19, 2019 Sheet 8 of 8 US 2019/0382802 A1 FIG . 7B Ser Ile Glu Val Gly Thr Ile Gly Gly Gly Thr Val Leu Glu Pro Gln 405 410 415 Gly Ala Met Leu Asp Leu Leu Gly Val Arg Gly Pro His Ala Thr Ala 420 425 430 Pro Gly Thr Asn Ala Arg Gin Leu Ala Arg Ile Val Ala Cys Ala Val 435 440 445 Leu Ala Gly Glu Leu Ser Leu Cys Ala Ala Leu Ala Ala Gly His Leu 450 455 460 Val Gin Ser His Met Thr His Asn Arg Lys Pro Ala Glu Pro Thr Lys 465 470 475 480 Pro Asn Asn Leu Asp Ala Thr Asp Ile Asn Arg Leu Lys Asp Gly Ser 485 490 495 Val Thr Cys Ile Lys Ser ( SEQ ID NO : 2 ) 500 US 2019/0382802 A1 Dec. 19 , 2019 GENETICALLY MODIFIED HOST CELLS pharmaceuticals . A major obstacle to high level terpenoid AND USE OF SAME FOR PRODUCING biosynthesis is the production of terpene precursors . In ISOPRENOID COMPOUNDS Saccharomyces cerevisiae, the mevalonate pathway pro vides for production of isopentenyl diphosphate ( IPP ) , CROSS -REFERENCE which can be isomerized and polymerized into isoprenoids and terpenes of commercial value . Other valuable precursors [ 0001 ] This application claims the benefit of U.S. Provi are also produced , including farnesyl diphosphate ( FPP ) and sional Patent Application No.60 /592,009 filed Jul. 27 , 2004 , geranylgeranyl diphosphate (GPP ) . However , much of the which application is incorporated herein by reference in its reaction flux is directed towards the undesired later steps of entirety . the sterol pathway , resulting in the production of ergosterol . FIELD OF THE INVENTION [0006 ] There is a need in the art for improved isoprenoid producing or isoprenoid precursor -producing host cells that [ 0002 ] The present invention is in the field of production provide for high - level production of isoprenoid compounds, of isoprenoid compounds, and in particular host cells that are as well as the polyprenyl diphosphate precursors of such genetically modified to produce isoprenoid compounds . compounds . The present invention addresses this need and BACKGROUND OF THE INVENTION provides related advantages . [ 0003 ] Isoprenoids constitute an extremely large and LITERATURE diverse group of natural products that have a common biosynthetic origin , i.e., a single metabolic precursor , iso [0007 ] U.S. Patent Publication No.